-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-04-17
Values as of: 2024-04-17
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.
Company Website : www.ftportfolios.com
Currency: USD
Country : USA
Inception Date: 19/06/2006
Primary Benchmark: NYSE Arca Biotechnology TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.55%
Management Expense Ratio: 0.57 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| NTRA | Natera Inc | 5.24 % |
| BRKR | Bruker Corporation | 4.11 % |
| ITCI | Intracellular Th | 4.08 % |
| HALO | Halozyme Therapeutics Inc | 3.90 % |
| UTHR | United Therapeutics Corporation | 3.80 % |
| MTD | Mettler-Toledo International Inc | 3.58 % |
| NBIX | Neurocrine Biosciences Inc | 3.57 % |
| EXEL | Exelixis Inc | 3.56 % |
| CORT | Corcept Therapeutics Incorporated | 3.50 % |
| WAT | Waters Corporation | 3.49 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
+0.25 (+0.18%) |
USD 37.76B |
| VHT | Vanguard Health Care Index Fun.. | 0.10 % |
+1.24 (+0.48%) |
USD 16.98B |
| XBI | SPDR® S&P Biotech ETF | 0.35 % |
+2.71 (+3.20%) |
USD 7.05B |
| IHI | iShares U.S. Medical Devices E.. | 0.43 % |
+0.01 (+0.02%) |
USD 5.55B |
| IXJ | iShares Global Healthcare ETF | 0.46 % |
+0.24 (+0.27%) |
USD 4.11B |
| IYH | iShares U.S. Healthcare ETF | 0.43 % |
+0.35 (+0.59%) |
USD 3.23B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
+0.28 (+0.42%) |
USD 2.94B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
+0.59 (+0.57%) |
USD 1.33B |
| IHF | iShares U.S. Healthcare Provid.. | 0.43 % |
-0.40 (-0.77%) |
USD 0.82B |
| IHE | iShares U.S. Pharmaceuticals E.. | 0.42 % |
+0.97 (+1.51%) |
USD 0.69B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| FBT:CA | First Trust NYSE Arca Bio.. | 99.99 % | 0.00 % |
N/A |
CAD 1.83M |
| FHM:CA | First Trust NYSE Arca Bio.. | 99.89 % | 0.78 % |
N/A |
CAD 1.71M |
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -9.08% | 9% | A- | 19% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -9.08% | 9% | A- | 18% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -9.10% | 14% | F | 22% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -9.10% | 14% | F | 19% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 5.26% | 25% | F | 52% | F | ||
| Dividend Return | 1.62% | 37% | F | 5% | F | ||
| Total Return | 6.88% | 25% | F | 39% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 3.44% | 23% | F | 55% | F | ||
| Dividend Return | 3.77% | 23% | F | 47% | F | ||
| Total Return | 0.33% | 35% | F | 8% | B- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 13.62% | 68% | D+ | 71% | C- | ||
| Risk Adjusted Return | 27.70% | 36% | F | 51% | F | ||
| Market Capitalization | 0.85B | 64% | D | 58% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
